Print preview Close
Showing 36 results
Archival DescriptionA therapeutic and economic assessment of Betaseron in multiple sclerosis
A therapeutic and economic assessment of Betaseron in multiple sclerosis
Abstract, poster, and presentations on MS research
Abstract, poster, and presentations on MS research
Benign multiple sclerosis : a 25-year retrospective analysis and redefinition
Benign multiple sclerosis : a 25-year retrospective analysis and redefinition
Clinical effectiveness of disease modifying treatment (DMT) that delays disability progression in relapsing/remitting-onset MS
Clinical effectiveness of disease modifying treatment (DMT) that delays disability progression in relapsing/remitting-onset MS
Conference schedule for MS research presentations
Conference schedule for MS research presentations
Correspondence and reports regarding Biogen / Axia Research
Correspondence and reports regarding Biogen / Axia Research
Cost-effectiveness of Interferon Beta-1B in slowing multiple sclerosis disability progression : first estimates
Cost-effectiveness of Interferon Beta-1B in slowing multiple sclerosis disability progression : first estimates
Cost-effectiveness of multiple sclerosis drugs in the "real world"
Cost-effectiveness of multiple sclerosis drugs in the "real world"
Dalhousie MS Research Group meeting minutes
Dalhousie MS Research Group meeting minutes
Disability progression in multiple sclerosis is faster than observed
Disability progression in multiple sclerosis is faster than observed
EDSS natural history atlas : multiple sclerosis disability progression in Nova Scotia, 1979-2004
EDSS natural history atlas : multiple sclerosis disability progression in Nova Scotia, 1979-2004
Effectiveness and cost-effectiveness of new drugs on multiple sclerosis disability progression in the "real world"
Effectiveness and cost-effectiveness of new drugs on multiple sclerosis disability progression in the "real world"
Effectiveness and cost-effectiveness of new drugs on multiple sclerosis disability progression in the "real world" : final report
Effectiveness and cost-effectiveness of new drugs on multiple sclerosis disability progression in the "real world" : final report
Effectiveness and cost-effectiveness of new multiple sclerosis drugs the "real world" : final report to Health Policy Research Program, Health Canada
Effectiveness and cost-effectiveness of new multiple sclerosis drugs the "real world" : final report to Health Policy Research Program, Health Canada
Email between Sarah Kirby and Murray Brown regarding modelling for research on drug efficacy in delaying disability progression in relapsing remitting onset MS
Email between Sarah Kirby and Murray Brown regarding modelling for research on drug efficacy in delaying disability progression in relapsing remitting onset MS
Estimates of MS disability progression natural history speed before and after applying censoring bias reduction methods to observational Nova Scotia EDSS-clinic-visit 1979-2010 data
Estimates of MS disability progression natural history speed before and after applying censoring bias reduction methods to observational Nova Scotia EDSS-clinic-visit 1979-2010 data
Estimates of MS disability progression natural history speed before and after applying censoring bias reduction methods to observational Nova Scotia EDSS-clinic-visit 1979-2010 data
Estimates of MS disability progression natural history speed before and after applying censoring bias reduction methods to observational Nova Scotia EDSS-clinic-visit 1979-2010 data
Evaluation of health-related quality of life utility measures in patients with multiple sclerosis
Evaluation of health-related quality of life utility measures in patients with multiple sclerosis
First-generation disease-modifying therapy exposure effects on disability burden in ambulatory relapsing-onset MS : fixed effects regression model estimates from 1979-2010 Nova Scotia data
First-generation disease-modifying therapy exposure effects on disability burden in ambulatory relapsing-onset MS : fixed effects regression model estimates from 1979-2010 Nova Scotia data
How effective are new drugs in delaying disability progression in relapsing remitting onset multiple sclerosis? A subgroup analysis
How effective are new drugs in delaying disability progression in relapsing remitting onset multiple sclerosis? A subgroup analysis
Information sinkholes on the road to representative estimates of MS disability progression speed ....
Information sinkholes on the road to representative estimates of MS disability progression speed ....
Letter of intent to Health Canada on Assessing the Effectiveness of Marketed Pharmaceutical Products in the "Real World"
Letter of intent to Health Canada on Assessing the Effectiveness of Marketed Pharmaceutical Products in the "Real World"
Measuring the consequences of MS in Canada : economic effects
Measuring the consequences of MS in Canada : economic effects
Modelling disease progression & treatment effects in multiple sclerosis within a cost-effectiveness study / Murray G. Brown & Chris Skedgel
Modelling disease progression & treatment effects in multiple sclerosis within a cost-effectiveness study / Murray G. Brown & Chris Skedgel
Modelling health outcomes in relapsing-remitting-onset multiple sclerosis cohorts treated with disease-modifying drugs that delay disability progression
Modelling health outcomes in relapsing-remitting-onset multiple sclerosis cohorts treated with disease-modifying drugs that delay disability progression
MS cost-effectiveness study correspondence and meeting notes
MS cost-effectiveness study correspondence and meeting notes
Multiple sclerosis disease-modifying drug and health care costs in Nova Scotia, 1989 -2003 / Vern Hicks, Murray G. Brown, I.S. Sketris
Multiple sclerosis disease-modifying drug and health care costs in Nova Scotia, 1989 -2003 / Vern Hicks, Murray G. Brown, I.S. Sketris
Multiple Sclerosis Integrated Database (MSID) datasets
Multiple Sclerosis Integrated Database (MSID) datasets
Multiple sclerosis net benefits feasibility study
Multiple sclerosis net benefits feasibility study
Multiple Sclerosis PharmacoEconomic Evaluation Tool (MS PEET) version 2 users manual
Multiple Sclerosis PharmacoEconomic Evaluation Tool (MS PEET) version 2 users manual
Murray G. Brown fonds
Murray G. Brown fonds
National Multiple Sclerosis Society (NMSS) COSTRIMS study
National Multiple Sclerosis Society (NMSS) COSTRIMS study
Observed DALYs avoided and QALYs gained in ambulatory definite relapsing onset multiple sclerosis cohort exposed to first-generation disease-modifying therapies
Observed DALYs avoided and QALYs gained in ambulatory definite relapsing onset multiple sclerosis cohort exposed to first-generation disease-modifying therapies
Serono Canada grant application and report
Serono Canada grant application and report
Serono grant application for Multiple Sclerosis Health Care Costs in Nova Scotia: A Population-based Life-cycle Study
Serono grant application for Multiple Sclerosis Health Care Costs in Nova Scotia: A Population-based Life-cycle Study
Treatment start and treatment duration as determinants of treatment program health outcomes and cost-effectiveness
Treatment start and treatment duration as determinants of treatment program health outcomes and cost-effectiveness